Impact of Von Willebrand Factor and Its Multimers on Angiogenesis
NCT ID: NCT04810702
Last Updated: 2024-03-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
90 participants
OBSERVATIONAL
2024-02-07
2024-08-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Frequency of Hemorrhages Associated With the Functional Anomalies of Willebrand Factor in Emergency Patients
NCT03070912
Cardiovascular and Venous Thromboembolism Disease in Patients with Von Willebrand Disease in the French West
NCT05773638
Update in VWD Laboratory Diagnosis
NCT03896997
Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases
NCT04119908
Prognostic Value of Implementing VCE on Top in Constitutional VWD-patients With GI-bleeding
NCT04466878
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients with von Willebrand disease
no intervention
no intervention
case control
no intervention
no intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
no intervention
no intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with von Willebrand disease proven by genetic analysis of the VWF gene.
* Lack of treatment that could interfere with angiogenesis.
* Patient informed by an information note sent to his home, with the possibility of objecting to the use of his blood samples in the context of research.
For the control:
* Patient with a normal coagulation report
* Absence of abnormal hemorrhagic symptoms
* Lack of notion of angiodysplasia.
* Lack of treatment that could interfere with angiogenesis.
* Patient informed by an information note sent to his home, with the possibility of objecting to the use of his blood samples in the context of research.
Exclusion Criteria
* Pregnant and lactating women.
* Blood transfusion or treatment with von Willebrand factor concentrates less than 7 days old.
* Treatment which may interfere with angiogenesis.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nantes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Nantes
Nantes, , France
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC20_0531
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.